Inventor
DAVID NATHANIEL
US25 patents
⚠️ This page may combine multiple inventors who share the name “DAVID NATHANIEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BUCK INST RES AGING
13 patentsUS10010546B2Jul 3, 2018
Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
BUCK INST RES AGING23 citations97
US9993472B2Jun 12, 2018
Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
BUCK INST RES AGING20 citations97
US9849128B2Dec 26, 2017
Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells
BUCK INST RES AGING24 citations97
US10478432B2Nov 19, 2019
Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye
BUCK INST RES AGING7 citations92
US9855266B2Jan 2, 2018
Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline
BUCK INST RES AGING12 citations92
US10258618B2Apr 16, 2019
Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
BUCK INST RES AGING5 citations84
US10213426B2Feb 26, 2019
Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population
BUCK INST RES AGING5 citations84
US9980962B2May 29, 2018
Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease
BUCK INST RES AGING6 citations84
US10413542B2Sep 17, 2019
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase
BUCK INST RES AGING4 citations83
US11980616B2May 14, 2024
Treating liver disease by selectively eliminating senescent cells
BUCK INST RES AGING0 citations73
US11351167B2Jun 7, 2022
Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue
BUCK INST RES AGING1 citations73
US11963957B2Apr 23, 2024
Treating cardiovascular disease by selectively eliminating senescent cells
BUCK INST RES AGING0 citations72
US12285427B2Apr 29, 2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor
BUCK INST RES AGING0 citations62
UNITY BIOTECHNOLOGY INC
11 patentsUS10195213B2Feb 5, 2019
Chemical entities that kill senescent cells for use in treating age-related disease
UNITY BIOTECHNOLOGY INC15 citations94
US10328073B2Jun 25, 2019
Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells
UNITY BIOTECHNOLOGY INC9 citations92
US10130628B2Nov 20, 2018
Treatment of joint pain
UNITY BIOTECHNOLOGY INC6 citations91
US10517866B2Dec 31, 2019
Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor
UNITY BIOTECHNOLOGY INC5 citations83
US10478433B2Nov 19, 2019
Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss
UNITY BIOTECHNOLOGY INC4 citations83
US10426788B2Oct 1, 2019
Chemical entities that kill senescent cells for use in treating age-related disease
UNITY BIOTECHNOLOGY INC2 citations73
US10550378B2Feb 4, 2020
Composition comprising a gene vector that selectively depletes P16 positive senescent cells
UNITY BIOTECHNOLOGY INC2 citations70
US10378002B2Aug 13, 2019
Replication conditional virus that specifically kills senescent cells
UNITY BIOTECHNOLOGY INC2 citations70
US11129838B2Sep 28, 2021
Methods of inhibiting pathological angiogenesis
UNITY BIOTECHNOLOGY INC2 citations68
US10588916B2Mar 17, 2020
Technology to inhibit vascular changes that lead to vision loss in the eye
UNITY BIOTECHNOLOGY INC2 citations68
US11865123B2Jan 9, 2024
Methods of inhibiting pathological angiogenesis
UNITY BIOTECHNOLOGY INC0 citations57